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Abstract
Irritable bowel syndrome (IBS) affects a large number of children throughout the world. The symptom expression of
IBS is heterogeneous, and several factors which may be interrelated within the IBS biopsychosocial model play a
role. These factors include visceral hyperalgesia, intestinal permeability, gut microbiota, psychosocial distress, gut
inflammation, bile acids, food intolerance, colonic bacterial fermentation, and genetics. The molecular and cellular
mechanisms of these factors are being actively investigated. In this mini-review, we present updates of these
mechanisms and, where possible, relate the findings to childhood IBS. Mechanistic elucidation may lead to the
identification of biomarkers as well as personalized childhood IBS therapies.
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Introduction
Chronic abdominal pain is highly prevalent affecting up
to 25 % of schoolchildren worldwide [1, 2]. Using con-
ventional diagnostic tools, the majority of children with
chronic abdominal pain will not have an organic eti-
ology; as a result, they are diagnosed as having an ab-
dominal pain-related functional gastrointestinal disorder
(FGID) [3, 4].
Based on the symptoms suffered by the individual, FGIDs
are classified further into functional dyspepsia, functional
abdominal pain, and irritable bowel syndrome (IBS) [3]. Of
the abdominal pain-related FGIDs, IBS is the most preva-
lent, encompassing approximately 60 % of children with a
FGID [5]. Based on the predominant stool form, IBS is fur-
ther phenotypically subtyped into IBS with constipation
(IBS-C), IBS with diarrhea (IBS-D), IBS mixed subtype
(IBS-M), and IBS un-subtyped (IBS-U) [6]. These subtypes
occur in children and adults with IBS; however, in children
IBS-C and IBS-U are more prevalent than in adults [7]. It is
generally believed that IBS subtyping increases the likeli-
hood of identifying underlying unique pathobiological
processes specific to each IBS subtype [6]. However, it
should be noted that IBS subtype may change over
12 months in up to 24 % of children [8].
There are several factors which may play a role in the
symptom expression in a child with IBS including: visceral
hyperalgesia, intestinal hyperpermeability, gut microbiome
composition, psychosocial distress, food intolerance, co-
lonic bacterial fermentation, genetics, and gut inflammation
[5, 9]. Each process may play a lesser or greater role in one
individual as compared to another; therefore, IBS is often
approached via a biopsychosocial model (Fig. 1) [10].
Investigators continue to actively explore several con-
current areas of potential IBS pathobiology. In this mini-
review, we present updates within several potential
pathobiological factors in IBS with an emphasis on the
underlying molecular and cellular mechanisms. When
possible, we focus on data and studies relevant specific-
ally to children. Further understanding cellular and mo-
lecular mechanisms may one day lead to both the
identification of reliable biomarkers as well as personal-
ized IBS therapies.
Visceral hypersensitivity
Visceral sensation mechanisms and pathways have been
extensively reviewed by others [11]. Communication of
sensory nerves responsive to noxious stimuli (chemical,
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mechanical, or inflammatory) with the central nervous
system occurs via vagal, pelvic, and splanchnic nerve
pathways [11, 12]. Splanchnic and pelvic nerve signals
are transmitted via spinal visceral afferents to the spinal
dorsal horn where they subsequently communicate to
the brain via several ascending pathways including the
spinothalamic, spinoreticular, and spinomesencephalic
tracts. Descending inhibitory pathways influence visceral
sensation by modulating (gating) the ascending visceral
afferent pathways [12]. Visceral sensation processing is
further modulated by mediators and receptors including
neurotransmitter receptors, cannabinoid receptors, opi-
oid receptors, gamma-aminobutyric acid receptors, glu-
tamate receptors, glucocorticoid receptors, inflammatory
receptors, and ion channel receptors [11]. Additional
psychological factors such as attention/distraction, ex-
pectations of pain, emotion, stress, and coping strategies
also play a role (Fig. 1).
Visceral hypersensitivity may be present in a subgroup
of children with IBS. Through the use of rectal barostat
studies, which inflate a balloon in the rectum while
measuring pressure and volume, some children with IBS
have been found to have increased visceral sensitivity
[13]. In a small rectal barostat study in children with IBS
(n = 10), Iovino et al. identified that emotional instability
(anxiety, depression, discontent, impulsiveness, and
anger) modulated visceral perception [14]. Supporting
this are data suggesting children with pain-related
FGIDs who had more anxiety and somatization also had
increased pain frequency and severity; however, the
study did not measure visceral sensitivity [15].
Abnormalities within the descending pain modulatory
system are increasingly considered to be important in the
development of the pro-nociceptive state encountered
with visceral hypersensitivity [12]. Williams et al. recently
found, using a diffuse noxious inhibitory control study de-
sign, that girls with IBS (in comparison to healthy girls)
had impaired pain inhibition [16]. Hypnotherapy (hypno-
sis with therapeutic intent) appears, in part, to use de-
scending inhibitory pathways for control of pain [17]
while also reducing psychological factors such as stress
[18]; it has demonstrated efficacy in several randomized
controlled trials for childhood IBS [19].
While the majority of work in new pharmacological
visceral pain therapies is occurring within animal
models, there are new emerging clinical therapies. For
example, efforts have focused on inflammatory receptors
known as tachykinin receptors, of which there are three
types [20]. Within a phase II randomized, placebo-
controlled, parallel group study, Ibodutant® (MEN
15596), a neurokinin 2 antagonist, demonstrated out-
come efficacy (overall IBS symptom relief for 3 of
4 weeks) in a post hoc analysis of adults with IBS-D with
pain [20]. However, it should be noted that in the overall
IBS population studied, Ibodutant® was not superior to
placebo. In infants with colic, an abstract has reported
that Nepadutant® (MEN-11420), a neurokinin 2 antag-
onist, had efficacy in a phase II, randomized, double
blind, placebo-controlled trial [21]. Though infants
with colic may go on to manifest childhood FGIDs
[22], there are currently no studies using neurokinin
2 antagonists in childhood IBS. We anticipate further
studies with new pharmacologic therapies directed at
modulating visceral pain.
In addition to drug development, alternative therapies
are now being investigated for their ability to modulate
visceral pain. Menthol, an active ingredient of pepper-
mint oil, may reduce visceral pain through ion channels
Fig. 1 The biopsychosocial model of irritable bowel syndrome. The circle represents the interrelated nature of the model. Several factors (in black
bold) are present and affect other factors as shown by the direction of the red arrows. Mechanisms related to these factors are in blue font within
the circle. The balance between pathogenic bacteria and commensal bacteria is in yellow. These factors ultimately come together and lead to IBS
symptoms. Figure is modified from Rodriguez-Fandino et al. [10] and reproduced by permission of Journal of Neurogastroenterology and Motility
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such as transient receptor potential ion channel melasta-
tin subtype 8 [23]. A recent meta-analysis of peppermint
oil identified an improvement in global assessment and
IBS scores in adults with IBS [24]. Given a previous suc-
cessful small, short-term study in children with IBS [25]
and a recent small pharmacodynamic study in children
with IBS [26], we anticipate further studies of pepper-
mint oil in children with IBS.
Genetic factors and serotonin signaling
Genetic factors in IBS recently have been reviewed in
detail and are beyond the scope of this review [27].
Therefore, we provide a brief overview with more focus
on genetics as they relate to serotonin signaling.
Relatives with a family history of IBS have a two- to
threefold increased risk for IBS [27]. Twin studies have
estimated the genetic heritability of IBS to range be-
tween 22 and 57 % [28] with higher prevalence seen
amongst monozygotic in comparison to dizygotic twins
[29]. The potential role of environmental contributions
is still being investigated.
Several genetic disturbances related to IBS have been
identified [27]. Perhaps the most extensive investigations
to date have related to 5-hydroxytryptamine (5-HT, sero-
tonin). Serotonin is a bioamine neurotransmitter primar-
ily produced in the gut which is important for
modulating intestinal motility, inflammation, and secre-
tion [30]. Serotonin is synthesized by tryptophan hy-
droxylase within enteroendocrine cells and enteric
neurons [31]. Under normal circumstances, the sero-
tonin transporter (SERT) from gene SLC6A4 terminates
5-HT action via uptake into enterocytes and serotonergic
neurons. However, genotypes which would alter SERT
expression have been identified. These include homozy-
gous genotypes of the promoter length polymorphism 5-
HT transporter-linked polymorphic region (5-HTTLPR)
which is upstream of SLC6A4. Short allele polymor-
phisms affect SLC6A4 transporter expression and have
been associated with IBS-D and IBS-C [27]. 5-HT levels
have been found to be markedly increased in rectal biop-
sies of adults with IBS-D who were homozygous for the
short allele for 5-HTTLPR [32]. However, the field is still
being actively investigated as a recent meta-analysis
identified that the long/long genotype of 5-HTTLPR is
associated with IBS-C but did not find associations of 5-
HTTLPR mutations with IBS-D [33].
Beyond the gut alone, the short allele of 5-HTTLPR
also is associated with several other factors including de-
pression, anxiety, neuroticism, anxiety, increased sympa-
thetic tone, decreased parasympathetic tone, post-
infectious IBS, and higher cortisol levels [27]. Whether
this and/or other serotonin-related mutations are found
in children with IBS is currently unknown.
Altered intestinal permeability
Intestinal permeability is regulated, in part, by inter-
epithelial tight junctions composed of protein com-
plexes. Within these protein complexes, three proteins
have received particular attention within IBS: occludin,
claudin-1, and zonula occludens-1 [34]. Though these
protein complexes were not specifically evaluated, in-
creased intestinal permeability has been identified in
children with IBS [35]. In adults with IBS, increased in-
testinal permeability correlates with increased visceral
hypersensitivity and abdominal pain symptoms [36].
Intestinal permeability recently has been found to be
regulated by a class of endogenously expressed noncod-
ing RNAs (21–23 nucleotides in length) known as
microRNAs. MicroRNAs regulate gene expression, in-
cluding gene expression of tight junction proteins. Spe-
cifically, in adults with IBS-D, by downregulating
nuclear factor-ĸβ-repressing factor and claudin-1 mRNA
expression, microRNA 29 increases intestinal barrier
permeability [37]. Further studies to understand the
unique role of microRNA 29 in those with IBS-D as
opposed to other subtypes are needed. In addition, it is
not currently known whether these molecules may serve
as biomarkers in children with IBS.
Nevertheless, within the field of gastroenterology, there
are increasing efforts to address pathology by improving
intestinal barrier function. In children with IBS, a random-
ized controlled trial demonstrated that Lactobacillus GG
improved both abdominal pain and intestinal permeability
[38]. In adults with IBS, glutamine increased claudin-1 ex-
pression in patients with IBS-D [34]. In adults with celiac
disease, Leffler et al. have studied the effect of larazotide
(an inhibitor of Vibrio cholera zonula occludens toxin)
which promotes tight junction assembly [39]. Though
there were mixed results, a low dose of larazotide in adults
with celiac disease on a gluten-free diet improved persist-
ent symptoms [39].
We anticipate there will be further efforts in children
with IBS to address increased intestinal permeability. In
addition to specific therapies directed at tight junction
proteins, there is increasing knowledge of other factors
that alter intestinal permeability such as stress and im-
mune activation (Fig. 1) [40].
Gut epithelial immune activation
Mast cells
Several studies in both children and adults with IBS have
identified increased gut epithelial immune activation in
those with FGIDs [35]. Perhaps the most compelling
data regarding immune activation relate to mast cells.
These cells release newly synthesized and stored media-
tors including cytokines, histamine, serotonin, prosta-
glandins, neuronal growth factor, proteases, tryptase,
and other bioactive substances (Fig. 2). These mast cell
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mediators may cause epithelial and neuromuscular dys-
function; this in turn promotes visceral hypersensitivity,
altered motility, and increased intestinal permeability
[41]. Enteric nerves have receptors for the mast cell me-
diators which lead to nociceptor activation, sensitization,
recruitment, and ultimately increased visceral hypersen-
sitivity (Fig. 2). Triggers of mast cell release include the
following: psychological stress via corticotropin-releasing
factor; immunoglobulins, such as IgE; neurotransmitters,
such as histamine; neuropeptides, such as substance P
and calcitonin-related gene peptide (Fig. 2); growth fac-
tors, such as nerve growth factor; biological molecules,
such as lipopolysaccharide; and physiochemical stimuli
such as pressure [41].
In adults with IBS, though not consistently identified,
mast cells in the terminal ileum and throughout the
colon may be found in increased numbers [42, 43].
These mast cells may be found adjacent to nerve fibers,
which lead credence to their potential pathophysiologic
role [41]. In adults with IBS, the number of mast cells
correlates with IBS abdominal pain symptoms [41]. Al-
though the number of mast cells in ileocolonic biopsies
did not differ between children with IBS and controls,
Di Nardo et al. found that in children with IBS there
was an increased number of mast cells in close proxim-
ity to nerves [44]. In addition, Di Nardo et al. found that
in children with IBS, the mast cell number in ileocolonic
biopsies correlated with both abdominal pain frequency
and severity [44].
Therapies directed toward stabilization of mast cells
have demonstrated efficacy. Cromolyn, in a small (n =
16) randomized crossover trial in adults with IBS, im-
proved abdominal pain severity [45]. In a randomized,
parallel, controlled trial in adults with IBS, ketotifen (a
mast cell stabilizer) both decreased visceral hypersensi-
tivity and improved intestinal symptoms [46]. However,
it is important to note that many of these improvements
were lost during multiple testing in the Klooker et al.
trial. Though mast cell stabilizers have not been evalu-
ated in children with IBS, a retrospective study of cypro-
heptadine, which has several properties including being
an H1 antagonist, ameliorated abdominal pain in chil-
dren with FGIDs including IBS [47]. Further studies
evaluating mast cell therapies are needed.
Humoral immune activation
Adults with IBS have been shown to have humoral immune
activation (Fig. 1). Adults with IBS-D on jejunal biopsy had
both a higher number and higher activation of mucosal B
lymphocytes and plasma cells [48]. This upregulation corre-
lated positively with bowel movement frequency, stool
form, and depression [48]. In a similar vein, the number of
CD3+, CD8+, and CD25+ lymphocytes (as well as mast
Fig. 2 Mast cell-nerve interactions in the human gut. Mast cells and nerves communicate bidirectionally, thereby modulating peristalsis and pain
signaling. The release of bioactive, pro-inflammatory mediators by mast cells results in a variety of neuronal effects including activation,
sensitization, and recruitment of nociceptors to the cell membrane, neurogenic inflammation, and neural sprouting. Ultimately, this leads to
visceral hypersensitivity. Neuronal activation triggers the release of neuropeptides and neurotransmitters, thereby further activating mast cells.
H1R = histamine-1 receptor; TRPV1 = transient receptor vanilloid 1; 5-HT3 = 5-hydroxytryptamine receptor; PAR2 = proteinase-activated
receptor-2; TrkA = receptor for nerve growth factor; TLR = toll-like receptor; NK1 = neurokinin 1 receptor; SP = substance P; CGRP = calcitonin-
related gene peptide; Ig = immunoglobulins; NGF = neuronal growth factor; PG = prostaglandins. Figure reproduced from “The role of mast cells
in functional GI disorders,” Wouters et al. [41] with permission from BMJ Publishing Group Ltd.© 2015 BMJ & British Society of Gastroenterology.
All rights reserved
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cells) has previously been found to be elevated in the co-
lonic mucosa of a subgroup of those with IBS [49].
These lymphocytes secrete cytokines. Secretion of IL-
1β from colonic CD3+/CD28+ T lymphocytes correlated
modestly with bowel habit dissatisfaction in adults with
IBS [50]. In adults with IBS induction of release of IL-6
(a pro-inflammatory cytokine) by pyridostigmine corre-
lated with symptom exacerbation [51]. Cytokines also
may have ties to psychosocial distress as adults with
IBS-D who had increased anxiety, and depression scores
were found to have higher TNF-α and IL-8 production
in peripheral blood mononuclear cells [52]. Zhen et al.
also found a correlation of these elevated cytokines with
epithelial cell dysfunction as measured by occludin pro-
tein levels [52]. Whether larger numbers of lymphocytes
or cytokines are found in children with IBS is currently
unknown.
Innate immune activation
Defensins are antimicrobial peptides involved in the innate
immune response [53]. They are stored in neutrophils,
macrophages, and epithelial cells. These molecules are ac-
tive against bacteria, fungi, and enveloped viruses [53]. A
recent study in adults with IBS (versus healthy controls)
found elevated human beta-defensin-2 levels in the stool,
akin to that seen in patients with ulcerative colitis [54].
Langhorst et al. also found elevated beta-defensin-2 within
the epithelial cells of those with IBS who had elevated fecal
levels [54]. Whether similar findings are seen in children
with IBS remains to be determined. Furthermore, therapies
to directly bolster the innate immune system have not yet
been conducted in subjects with IBS.
Enteroendocrine cells
Another area of neuroimmune activation in IBS involves
enteroendocrine cells. The role of these cells in IBS re-
cently has been extensively reviewed [55]. Briefly, enter-
oendocrine cells form part of the epithelial barrier from
the stomach through the rectum. These cells are com-
posed of different types dependent on location and their
secreted neurohormonal mediators. These mediators in-
clude serotonin, somatostatin, ghrelin, polypeptide YY,
cholecystokinin, motilin, gastric inhibitory peptide, pan-
creatic polypeptide, and enteroglucagon amongst others.
Secretion of these mediators is activated by luminal
stimuli such as nutrients and gut bacteria. These media-
tors are secreted into the lamina propria where they may
have either local paracrine effects or, via blood, endo-
crine effects. Through their interaction with each other
and the enteric, autonomic, and central nervous systems,
these cells regulate several important gastrointestinal
functions including visceral sensation, gut motility, intes-
tinal secretion, intestinal absorption, nutrient uptake,
and immunological defense [55].
Abnormalities in endocrine cell densities in the stom-
ach, duodenum, ileum, colon, and rectum in adults with
IBS have been found by investigators [55]. These abnor-
malities may vary by IBS subtype; for example, ghrelin-
containing endocrine cells are higher in number per
microscopic high-power field in adults with IBS-D but
lower in adults with IBS-C [56]. In addition, certain
chromogranins and secretogranins, which are proteins
that can be secreted by enteroendocrine cells and serve
as a markers for activity of the enteric neuroendocrine
system, have been found to be elevated in adults with
IBS [57]. Given both these cell density abnormalities and
expression of protein mediators, it has been postulated
that enteroendocrine cells may have a causative role in
IBS. Similar findings have not been reported in children
with IBS to date. In addition, there have not been any
trials directed specifically at enteroendocrine cell func-
tion in IBS. Nevertheless, we anticipate that further work
in this area will emerge over the next few years.
Diet in IBS
Carbohydrate malabsorption as a pathway toward gener-
ation of symptoms in IBS has received a lot of recent at-
tention, particularly in light of the efficacy of a low
fermentable, oligosaccharide, disaccharide, monosac-
charide, and polyols (FODMAP) diet in treating abdom-
inal pain in IBS [58]. FODMAP carbohydrates include
lactose, fructose, fructans, galactans, and polyols such as
sorbitol. When ingested, they have both an intraluminal
fermentation (gas-producing) and osmotic effect [59]. It
is these physiologic changes which are believed to ex-
acerbate IBS symptoms.
Diets which eliminate one substrate (e.g., lactose) at a
time have not demonstrated efficacy in randomized con-
trolled trials for childhood FGIDs [60]. However, elimin-
ation of a more comprehensive group appears to be
more successful. A low FODMAP diet has demonstrated
efficacy in ameliorating GI symptoms in children and
adults with IBS in double blind, randomized controlled
trials [61, 62]. In addition, low FODMAP diets alter the
gut microbiome composition. One study found that a 4-
week low FODMAP diet decreased luminal Bifidobac-
teria versus a habitual diet [63]. Another study in adults
with IBS during a randomized, crossover, double blind
trial found decreases in total bacterial abundance and di-
versity on the low FODMAP diet versus a typical Aus-
tralian diet [62]. The role of these changes in the gut
microbiome in affecting IBS symptoms while on the low
FODMAP diet remains to be elucidated.
Lactose (one of the FODMAP carbohydrates) has
received attention for many decades as a potential cul-
prit for inducing gastrointestinal symptoms. Lactose
malabsorption is not more prevalent in adults with IBS.
Kumar et al. evaluated the prevalence of known lactase
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polymorphisms in those with IBS in comparison to
healthy controls and found a similar frequency between
groups [64]. However, underlying IBS pathological fac-
tors may play a role in lactose malabsorption symptom
expression. Yang et al. evaluated lactose malabsorption
in adults with IBS-D and healthy adults via a random-
ized blinded crossover trial; both groups had the lactase
non-persistence polymorphism (C/C-13910). Subjects
received doses of 10, 20, and 40 g of lactose [65]. In
addition, they underwent hydrogen breath testing to
identify lactose malabsorption, rectal barostat testing to
measure visceral hypersensitivity, and ileocolonic biop-
sies to assess neuroimmune activation. Yang et al. found
that those with an increase in gastrointestinal symptoms
in response to lactose malabsorption had both increased
visceral hypersensitivity and increased ileocolonic mast
cells compared to both healthy controls and those with
IBS who had no increase in GI symptoms following lac-
tose malabsorption [65].
Dietary fiber supplementation, acting as a bulking
agent, has long been proposed as a therapy for IBS.
Based on meta-analyses and systematic reviews, the effi-
cacy of fiber treatment in IBS is mixed; conclusions vary
based on the different types of fiber used and, in part,
on the different review methods employed [66–71]. Al-
though not conclusive, data suggest that psyllium, a sol-
uble fiber, reduces abdominal pain and/or improves
stooling symptoms in adults with IBS [70–72]. A prelim-
inary report suggests efficacy for psyllium fiber supple-
mentation in children with IBS [73].
Bile acids
The role of bile acids in gut physiology and potential role
in FGIDs has recently been reviewed [74, 75]. Briefly, bile
acids are steroid-derived detergent molecules produced
within the liver and secreted into the intestinal lumen that
aid in fat digestion. Primary bile acids (produced by the
liver) include both chenodeoxycholic acid (CDCA) and
cholic acid. In normal physiologic conditions ~95 % of se-
creted bile acids are absorbed in the ileum via the ileal bile
acid transporter and become part of the enterohepatic cir-
culation. Within the ileal enterocyte bile acids induce ex-
pression of nuclear farnesoid X receptor (FXR); this in
turn leads to expression of fibroblast growth factor 19
(FGF-19). FGF-19 is secreted and activates fibroblast
growth factor receptor 4 on the hepatocyte membrane;
this is followed by downregulation of both cholesterol 7
alpha-hydroxylase and subsequent bile acid synthesis.
Therefore, bile acids absorbed in the ileum normally have
negative feedback on hepatic bile acid production.
Primary bile acids that reach the colon such as CDCA
may have both potent colonic secretory and motor
stimulatory effects [76]. However, the majority of bile
acids that are not absorbed in the ileum are believed to
undergo deconjugation and dihydroxylation by colonic
microbiota, leading to the formation of secondary bile
acids: deoxycholic acid and lithocholic acid. As a result,
the potential effects of primary bile acids may be altered.
For example, cholic acid does not have colonic secretory
effects, whereas following its conversion to deoxycholic
acid by colonic microbiota, it does [77].
Altered bile acid secretion/absorption and/or metabol-
ism may affect gastrointestinal physiology in those with
FGIDs. In a recent meta-analysis, bile salt malabsorption
(measured via 23-seleno-25-homotaurocholic acid testing)
was found in 28.1 % of adults with IBS-D [78]. Shin et al.
demonstrated that adults with IBS-D placed on a high-fat
diet (versus those with IBS-C) have higher amounts of
both fecal fat and fecal unconjugated secretory bile acids
[79]. Though not yet studied in children with IBS one
study in children with functional constipation identified
that a small subset had excessive sulfation of CDCA [80].
Given the secretory capability of CDCA and its loss fol-
lowing sulfation the authors hypothesized that this may
contribute to constipation [80]. A small open-label study
of the low FODMAP diet in children with IBS found those
who had marked improvement (versus those who did not)
while on the diet had higher amounts (amongst other me-
tabolites) of fecal dehydroxylithocholate [9]. Future studies
regarding bile acids and their subsequent physiologic
effects in children with IBS are needed.
In open-label studies in adults with bile acid malab-
sorption, bile acid sequestrants such as colestipol have
shown efficacy [81]. In addition, obeticholic acid (an
FXR agonist) used in a small study of adults with IBS-D
with bile acid diarrhea demonstrated both an increase in
FGF19 and improvements in several clinical parameters
including median stool frequency, stool form, and diar-
rhea [82]. Studies with these interventions have not been
conducted in children with IBS to date.
CDCA has been found to have several beneficial effects
in adults with IBS-C including acceleration of colonic
transit, increased stool frequency, and loosening of stool
consistency [83]. Using an ileal bile acid transporter in-
hibitor (thereby increasing bile acids in the colon) within a
phase II trial for adults with chronic idiopathic constipa-
tion, Chey et al. demonstrated an improvement in both
stool frequency and constipation-related symptoms [84].
We anticipate further studies attempting to increase co-
lonic secretory bile acid effects in subjects (both adults
and children) with IBS-C in the future.
Gut microbiome
The gut microbiome (collection of microbiota and their
genetic material) and its role in health and disease are
being increasingly recognized. The gut microbiome
composition of adults and children with IBS (versus
healthy controls) has been found to be different [85, 86].
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Using both 16s rRNA pyrosequencing and PhyloChip
technology on fecal samples from children with IBS (versus
healthy controls), Saulnier et al. found a significantly greater
percentage of the class Gammaproteobacteria (such as H.
parainfluenzae) as well as a novel Ruminococcus-like
microbe [86]. In addition, Saulnier et al. found that in
children with IBS, microbiome composition correlated
with both abdominal pain severity and frequency; more-
over, microbiome composition was also able to differen-
tiate those with an IBS-U versus IBS-C subtype. Gut
microbiome composition was potentially found to be
important as a biomarker for improvement on a low
FODMAP diet; children who markedly improved had a
different microbiome composition as compared to those
who did not [9, 61].
The gut microbiome has several functions in health in-
cluding fermentation/degradation of undigested proteins
and carbohydrates, hydrogen disposal, and bile acid trans-
formation [87]. When performing these functions, the
microbiome produces several metabolites including but
not limited to short-chain fatty acids; gases, such as hydro-
gen sulfide; and secondary bile acids derived from primary
bile acids. Through their presence and metabolic function,
gut microbiota may play a role in several of the patho-
logical factors covered so far in this review including dys-
regulated intestinal immune function, chronic low-grade
mucosal inflammation, increased gut permeability, psy-
chosocial distress, and visceral hypersensitivity [41, 87,
88]. Further work to elucidate the mechanisms of action
of the gut microbiome and/or their metabolites within the
biopsychosocial model of IBS (Fig. 1) is needed.
Therapies which are directed toward the microbiome
such as probiotics have demonstrated efficacy in children
with IBS. A recent meta-analysis of Lactobacillus rhamno-
sus GG in children with IBS found a significantly higher
rate of treatment responders (no pain or improvement in
pain) in those receiving the probiotic versus placebo [89].
In a multicenter, randomized, placebo-controlled, double
blind, crossover study in children with IBS, VSL#3 signifi-
cantly ameliorated gastrointestinal symptoms [90]. The
mechanisms involved with these improvements through
the use of probiotics remain largely to be elucidated.
Summary
Children with IBS may have several interacting factors
which play a role in the pathogenesis of their symptoms.
These factors are being actively investigated and, given
their interrelated nature, are better understood when
placed within the context of the biopsychosocial model
(Fig. 1). Underpinning these factors are cellular and mo-
lecular mechanisms. Future investigations of these mecha-
nisms can be challenging given the likely heterogeneous
etiologies driving the symptoms of IBS. Ideally, mecha-
nisms should not be investigated in isolation; rather,
interrelationships can be investigated/accounted for
within the biopsychosocial model. These mechanisms,
when elucidated further, may lead to identification of bio-
markers and personalized therapies for children with IBS.
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